Vigamox Treatment for Ocular Graft-Versus-Host Disease
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
In this study the investigators seek to prospectively measure the response of ocular
graft-versus-host disease (GVHD) patients to treatment with topical Vigamox. The
investigators will accomplish this by enrolling patients with bilateral ocular GVHD and
treating one eye with topical Vigamox and the other eye with a placebo eye drop. By assessing
the response to treatment with Vigamox, the investigators hope to identify a role for topical
antibiotic treatment in ocular GVHD.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination